26 May 2016 - But there’s good reason to hope that may change very soon.

A massive new study of drug candidates sheds light on which experimental therapies are most likely to eventually reach the market.

The report was compiled by biotech’s largest trade association, the Biotechnology Innovation Organization (BIO), with the help of business intelligence firms BioMedTracker and Amplion, and it found that drugs for blood disorders have the highest probability of ultimately winning FDA approval. Meanwhile, cancer drugs have the lowest chance of receiving the go-ahead.

For more details, go to: http://fortune.com/2016/05/26/drugs-most-likely-to-be-approved/?xid=yahoo_fortune